<DOC>
	<DOCNO>NCT00918515</DOCNO>
	<brief_summary>This Phase I , single centre , open label study ass safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics intravenous AZD3043 single ascending dose healthy male volunteer .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability Pharmacokinetics Pharmacodynamics AZD3043</brief_title>
	<detailed_description />
	<criteria>Healthy male subject age 18 45 year suitable vein cannulation repeat venepuncture Predose assessment judge without remark investigator Have Body Mass Index ( BMI ) 19 30 kg/m2 weight least 50kg 100kg After adequate time ( least 15 minute ) rest supine position , abnormal vital sign define follow : · Systolic blood pressure ( BP ) &gt; 140 mm Hg.· Diastolic BP &gt; 90 mm Hg . Heart rate &lt; =55 &gt; 85 beat per minute Subjects compromise airway respiratory function evidence presence Class 3 4 Airway , Sleep Apnoea , Neck circumference &gt; 16.5 inch ( 42 cm ) , Asthma , Active recent ( 2 week ) respiratory infection , know chronic respiratory infection , know chronic respirator Lack normal phenotype butyrylcholinesterase ( pseudocholinesterase )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Sedation</keyword>
	<keyword>Anaesthesia</keyword>
	<keyword>Safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>healthy male volunteer</keyword>
</DOC>